Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.

Bhatia S, Landier W, Hageman L, Kim H, Chen Y, Crews KR, Evans WE, Bostrom B, Casillas J, Dickens DS, Maloney KW, Neglia JP, Ravindranath Y, Ritchey AK, Wong FL, Relling MV.

Blood. 2014 Oct 9;124(15):2345-53. doi: 10.1182/blood-2014-01-552166. Epub 2014 May 14.

2.

Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group.

Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR, Hanby CL, Leisenring W, Yasui Y, Kornegay NM, Mascarenhas L, Ritchey AK, Casillas JN, Dickens DS, Meza J, Carroll WL, Relling MV, Wong FL.

J Clin Oncol. 2012 Jun 10;30(17):2094-101. doi: 10.1200/JCO.2011.38.9924. Epub 2012 May 7.

3.

Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.

Bhatia S, Landier W, Hageman L, Chen Y, Kim H, Sun CL, Kornegay N, Evans WE, Angiolillo AL, Bostrom B, Casillas J, Lew G, Maloney KW, Mascarenhas L, Ritchey AK, Termuhlen AM, Carroll WL, Wong FL, Relling MV.

JAMA Oncol. 2015 Jun;1(3):287-95. doi: 10.1001/jamaoncol.2015.0245.

4.

It takes a village.

Winick N.

Blood. 2014 Oct 9;124(15):2316-7. doi: 10.1182/blood-2014-05-576900.

6.

The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.

Clemmensen KK, Christensen RH, Shabaneh DN, Harila-Saari A, Heyman M, Jonsson OG, Wesenberg F, Rosthøj S, Schmiegelow K; Nordic Society of Pediatric Hematology, Oncology (NOPHO).

Pediatr Blood Cancer. 2014 Apr;61(4):653-8. doi: 10.1002/pbc.24867. Epub 2013 Nov 22.

PMID:
24265159
7.

Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U; Nordic Society of Paediatric Haematology and Oncology (NOPHO).

J Pediatr Hematol Oncol. 2009 Jun;31(6):385-92. doi: 10.1097/MPH.0b013e3181a6e171.

PMID:
19648786
8.
10.
11.
12.

Electronic monitoring of medication adherence in early maintenance phase treatment for pediatric leukemia and lymphoma: identifying patterns of nonadherence.

Rohan JM, Drotar D, Alderfer M, Donewar CW, Ewing L, Katz ER, Muriel A.

J Pediatr Psychol. 2015 Jan-Feb;40(1):75-84. doi: 10.1093/jpepsy/jst093. Epub 2013 Dec 23.

13.

A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients - results of a randomized clinical trial.

Hanff LM, Mathot RA, Smeets O, Postma DJ, Ramnarain S, Vermes A, Pieters R, Zwaan CM.

Int J Clin Pharmacol Ther. 2014 Aug;52(8):653-62. doi: 10.5414/CP202054.

PMID:
24800919
14.
15.

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R; Nordic Society for Paediatric Haematology and Oncology.

Blood. 2009 Jun 11;113(24):6077-84. doi: 10.1182/blood-2008-11-187880. Epub 2009 Feb 17.

16.

A grounded theory of the process of adherence to oral chemotherapy in Hispanic and caucasian children and adolescents with acute lymphoblastic leukemia.

Landier W, Hughes CB, Calvillo ER, Anderson NL, Briseño-Toomey D, Dominguez L, Martinez AM, Hanby C, Bhatia S.

J Pediatr Oncol Nurs. 2011 Jul-Aug;28(4):203-23. doi: 10.1177/1043454211409582. Epub 2011 Jun 8.

17.

A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).

Bell BA, Brockway GN, Shuster JJ, Erdmann G, Sterikoff S, Bostrom B, Camitta BM; Pediatric Oncology Group study (now The Children's Oncology Group).

Pediatr Blood Cancer. 2004 Aug;43(2):105-9.

PMID:
15236274
18.

Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia.

Schmiegelow K.

Pediatr Hematol Oncol. 1991 Oct-Dec;8(4):301-12. Erratum in: Pediatr Hematol Oncol 1992 Apr-Jun;9(2):following 198.

PMID:
1782110
19.

Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.

Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE.

Blood. 1999 May 1;93(9):2817-23.

20.

A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia.

Adamson PC, Zimm S, Ragab AH, Balis F, Steinberg SM, Kamen BA, Vietti TJ, Gillespie A, Poplack DG.

Cancer Chemother Pharmacol. 1992;30(2):155-7.

PMID:
1600597
Items per page

Supplemental Content

Write to the Help Desk